INTRODUCTION
Following the isolation of respiratory syncytial virus (RSV) in 1956, its significance as a human pathogen in infants and the elderly has been established (Oshansky et al., 2009) . RSV is the primary cause of hospitalization for respiratory tract illness in young children, with infection rates approaching 70 % in the first year of life (Robinson et al., 2012) . Despite this substantial disease burden, no vaccines are currently available. Therefore, development of effective RSV vaccines is urgently needed.
In the 1960s, a formalin-inactivated RSV vaccine was used to immunize children, which elicited non-protective, pathogenic antibodies. Immunized infants experienced increased morbidity after subsequent RSV exposure (Sawada et al., 2011) . This enhanced respiratory disease was thought to be due to low-affinity, poorly neutralizing antibodies and a biased T helper (T h ) type 2 immune response to the RSV fusion (F) protein, which correlated with enhanced lung pathology when compared with live RSV infection (Collins & Melero, 2011; Kamphuis et al., 2012) . The only currently available, effective prophylaxis for RSV is a humanized mAb Synagis (palivizumab; MedImmune) which is specific for the RSV F protein. However, use of palivizumab may produce an allergic reaction, which is potentially life threatening (Fuller & Del Mar, 2006 . Various strategies for the development of an RSV vaccine have been considered. Influenza viruses are attractive candidate viral vaccine vectors because they elicit strong humoral and cell-mediated immune responses, and can be manipulated by reverse genetics. Additionally, several groups have reported the use of recombinant influenza viruses as viral vectors for Chlamydia, tuberculosis, malaria and cancer vaccines (He et al., 2007; Miyahira et al., 1998; Sereinig et al., 2006; Strobel et al., 2000) . Furthermore, many exogenous genes, such as those for bacterial chloramphenicol acetyltransferase (CAT) (Percy et al., 1994) , the human immunodeficiency type 1 antigens p17 Gag and Rev (de Goede et al., 2009) , the Mycobacterium tuberculosis early secretory antigenic target (ESAT-6) (Stukova et al., 2006) , biologically active human IL-2 (Kittel et al., 2005) , various influenza virus genes (Horimoto et al., 2004; Li et al., 2005) , and GFP (Kittel et al., 2004) , have been tested using a recombinant influenza virus as a vector. The RSV F protein is one of the major antigens expressed on the virion surface, and contains many neutralizing antibody epitopes and several T-cell epitopes (Singh et al., 2007) . Therefore, we hypothesized that a recombinant influenza virus containing an F protein or F protein epitopes would induce strong RSV-specific immune responses and immunity. In the present study, we describe the construction and characterization of rFlu/RSV/F -a recombinant influenza virus vector expressing F protein epitopes of RSV. Using reverse genetics, a recombinant influenza virus that contained the influenza virus PR8 backbone and RSV F protein epitopes was generated and inserted into the non-structural NS1 protein, encoded by the NS gene. The immune responses against influenza and RSV were investigated in BALB/c mice immunized with rFlu/ RSV/F.
RESULTS AND DISCUSSION
In the present study, we describe the construction and characterization of a recombinant influenza virus (rFlu/ RSV/F) containing RSV F protein epitopes produced using reverse genetics. As shown in Fig. 1(a) , the NS gene segment of the recombinant influenza viruses contains the RSV F protein epitopes. The incorporation of RSV F protein epitopes was confirmed by Western blotting with RSV polyclonal antibodies (Fig. 1b) . The rFlu/RSV/F virus had a typical lipid bilayer membrane and spherical shape with surface spikes (Fig. 1c ). The rescued virus had a peak size distribution of 80-120 nm (Fig. 1d) . Thus, the rFlu/ RSV/F virus was similar to the influenza virus in terms of both morphology and size. Additionally, the antigenic properties of the rFlu/RSV/F virus were stable for at least 1 year at 280 u C (data not shown).
Next, the expression of NS1 and the nuclear export protein (NEP) by the rFlu/RSV/F virus was determined with an immunofluorescent assay. As shown in Fig. 2 , the rFlu/RSV/ F virus was able to express NS1 and NEP in MDCK cells 24 h post-infection. NS1 and NEP staining was detected in the cytoplasm, and no staining was detected following RSV infection. To further evaluate the relationship between cytopathicity and viral replication in the tested cell lines, the growth kinetics of rFlu/RSV/F and PR8 viruses were compared. MDCK, A549 and CNE-2Z cells infected with the rFlu/RSV/F virus or the PR8 influenza virus at m.o.i. 0.002 were incubated at 35 u C in 5 % CO 2 , and virus titres were determined by p.f.u. assay at 12, 24, 48 and 72 h postinfection. rFlu/RSV/F virus reached a peak titre of 10 7.2 p.f.u. ml 21 48 h after MDCK cell infection (Fig. 3a) . The rescued viruses could also replicate effectively in A549 ( Fig. 3b ) and CNE-2Z cells ( Fig. 3c) A T h 2-biased immune response is thought to be an important factor in RSV disease. Here, recombinant rFlu/ RSV/F immunization induced T h 1-type cytokines, which might play an important role in immune regulation in anti-infection immune responses. The RSV F-specific immune response in splenocytes was examined using IL-2, IL-4, IL-5, IFN-c and TNF-a ELISA kits 2 weeks after boost immunization. As shown in Fig. 5 , the levels of the T h 1 cytokines IL-2, IFN-c and TNF-a were significantly higher than the T h 2 cytokines IL-4 and IL-5 when splenic lymphocytes (SPLs) were restimulated with RSV strain A2. However, these cytokines were undetectable when culture medium was used for restimulation. Thus, our rFlu/RSV/F candidate vaccine induced high-level T h 1 responses, but relatively low-level T h 2 responses. This is encouraging because enhanced disease after RSV challenge is reportedly related to elevated T h 2-associated responses (Schmidt et al., 2012) . Our data also reveal that the observed immune responses are dependent upon the rFlu/RSV/F vector, as these responses do not occur in splenocytes isolated from mice immunized with the PR8 influenza virus alone (data not shown).
In conclusion, recombinant influenza viruses are promising vaccine vector candidates that may be used for the induction of antibody and cell-mediated immune responses. Additional research into the induction of humoral, cellular and mucosal immune responses is required to further develop recombinant influenza viruses as vaccine candidates, and the most effective rFlu/RSV/F vaccination strategy, including the optimum route and schedule of immunization, should be further investigated. Overall, we demonstrate that a recombinant influenza virus containing RSV proteins can trigger a robust immune response. We therefore conclude that the rFlu/RSV/F virus is a promising vaccine candidate, and its protective effects should be confirmed in the cotton rat and monkey models.
METHODS
Viruses and cells. The WT influenza virus A/PR/8/34 (PR8) was inoculated into the allantoic cavity of 9-day-old specific-pathogenfree (SPF) chicken eggs (Laboratory Animal Center, Beijing, China). Three days later, allantoic fluids were harvested and stored at 270 uC until use. The RSV strain A2 (subgroup A) was obtained from the American Type Culture Collection (ATCC) and cultured in human laryngeal epithelial (HEp-2) cells with Dulbecco's modified Eagle's medium (DMEM)/F-12 (1 : 1) medium (Gibco) containing 10 % FBS at 37 uC with 5 % CO 2 . RSV virus supernatants were collected on day 5 post-infection with centrifugation at 5500 g for 30 min at 4 uC and stored at 270 uC. COS-1 cells (African green monkey kidney cells transformed by SV40) and MDCK (Madin-Darby canine kidney) cells were obtained from the ATCC and maintained in essential medium (DMEM; Sigma) containing 10 % FBS at 37 uC in 5 % CO 2 . The medium was supplemented with 100 IU penicillin ml 21 and 100 mg streptomycin ml 21 .
Construction of recombinant rFlu/RSV/F. RSV F protein epitopes (F 205-223 : PIVNKQSCRISNIETVIEF; F 255-278 : SELLSLINDMPITNDQKKLMSNNV) were inserted into the influenza virus NS gene. Notably, an overlapping stop-start pentanucleotide cassette (TAATG) was introduced. The coding sequence of the RSV F epitopes was blunt-end cloned downstream of the stop-start cassette to create the pNS1-F plasmid. The sequence of the recombinant pNS1-F plasmid was synthesized by the Shanghai Sangon Company. The cDNA of recombinant pNS1-F plasmid was cloned into the BsmBI site of pHW2000 and the resulting clone was confirmed by DNA sequencing (Chen et al., 2010) . Positive plasmids carrying eight gene segments of the PR8 virus (pHW191-pHW198) were as described previously (Hoffmann et al., 2001 ).
Rescue of the infectious rFlu/RSV/F viruses. COS-1 and MDCK cells were co-cultured in culture dishes at a ratio of 1 : 1. Transfection of plasmid cDNA was performed using the Effectene transfection HI antibody titres (a) were detected using 0.5 % turkey erythrocytes. NT antibodies (b) were determined using RSV strain A2 (subgroup A). NT titres that resulted in a 50 % reduction in plaques are expressed as 10 n . *P,0.01, **P,0.001. Influenza A virus expressing RSV F epitopes reagent (Qiagen) by mixing 0.2 mg of each plasmid with 8 ml Effectene reagent diluted in 100 ml DMEM. rFlu/RSV/F was generated by reverse genetics based on the gene segments of influenza A/PR/8/34 as described previously (Yang et al., 2011) . These viruses were amplified in SPF chicken embryos. Allantoic fluid was collected on day 3 postinfection by centrifugation at 1600 g for 20 min at 4 uC. Viruses were concentrated using an ultrafiltration membrane package (Pall) and purified on a 20-30-60 % discontinuous sucrose gradient at 30 000 g for 3 h at 4 uC. Bands between 30 and 60 % were collected, and then diluted with PBS. The haemagglutination titre was recorded, and the TCID 50 was determined by serial titration of rFlu/RSV/F virus in MDCK cells and calculated with the Reed-Muench method (Neumann & Kawaoka, 2001 ).
Western blotting and electron microscopy. Recombinant rFlu/ RSV/F was characterized by Western blotting and electron microscopy. Expression of NS1-F protein in concentrated and purified rFlu/ RSV/F was evaluated by Western blotting as described by Sawada et al. (2011) . A polyclonal goat anti-RSV F protein (diluted 1 : 1000, ab20745; Abcam) was used to probe RSV F protein epitopes. For size determinations, negative staining of rFlu/RSV/F was performed, followed by transmission electron microscopy.
Virus growth. To assess viral replication, MDCK, A549 and CNE-2Z cells were infected with rFlu/RSV/F and WT PR8 (m.o.i. 0.002) viruses, and the plates were incubated at 35 uC in 5 % CO 2 . Cell culture supernatants were harvested every 12 h, and virus titres were assayed and expressed as p.f.u. ml 21 .
Immunofluorescence assay. MDCK cells were infected with rFlu/ RSV/F virus at m.o.i. 0.01 and harvested at 24 h. Cells were fixed with 4 % paraformaldehyde for 30 min, permeabilized with 0.1 % Triton X-100 for 5 min and blocked with 1 % BSA in PBS for 1.5 h. NS1-23-1 mAb (Santa Cruz) was used and the cells incubated for 1 h at 37 uC. The cells were washed extensively with wash buffer (PBS containing 0.2 % BSA and 0.1 % Triton X-100) and stained with FITCconjugated (Jackson ImmunoResearch) AffiniPure Goat AntiMouse second antibodies; thereafter, NEP polyclonal antibody (GeneTex) was used, followed by DyLight 594 (EarthOx) AffiniPure Goat Anti-Rabbit second antibodies. Images were captured with a laser scanning microscope.
Immunogenicity in vivo. Female BALB/c mice (Animal Experimental Center) aged 6-8 weeks were used in this study. Groups of mice (12 per group) were immunized intranasally twice with 1610 4 or 1610 5 TCID 50 of the rFlu/RSV/F virus in a 20 ml volume at intervals of 4 weeks. Blood samples were collected before immunization, 4 weeks after prime immunization and 2 weeks after boost immunization. SPL suspension samples were also collected 2 weeks after boost immunization. All animal experiments were conducted under the guidelines of the Academy of Military Medical Sciences Institutional Animal Care and Use Committee.
To detect rFlu/RSV/F-specific antibodies in the serum, an HI assay was performed by standard methods using 4 haemagglutination (HA) units of PR8 influenza virus in V-bottom, 96-well microtitre plates with 0.5 % turkey erythrocytes (Webster et al., 1991) . The inhibition of HA at the highest serum dilution was defined as the HI titre for the sample. All experiments were performed three times.
NTs against RSV were performed using the 50 % plaque reduction assay, with the RSV strain A2. Mice sera were complement inactivated, diluted serially by 1 : 2 each step and mixed with an equal volume of RSV (100 p.f.u.). The mixtures were inoculated onto HEp-2 cell monolayers in six-well plates. The protocol was that of Jones et al. (2012) . Plaques were counted and NT antibody titres were calculated as the reciprocal of the serum dilution that demonstrated a 50 % reduction in plaque number. All experiments were performed three times.
Cytokine assay. SPL suspensions were plated in 96-well plates at 1610 7 cells per well, followed by restimulation with RSV or medium as a negative control. The viral antigen concentration used was 5 mg ml 21 . Cells were incubated at 37 uC for 3 days and supernatants were collected for detection of cytokines. ELISA kits (Dakewe Biotech) for T h cytokines (IL-2, IL-4, IL-5, IFN-c and TNF-a) were used to assay cytokine production.
Statistics. GraphPad Prism 5 software was used to analyse the data. ANOVA was used and differences were deemed statistically significant at P,0.05. Antibody titres for each group and error bars extending to the upper 95 % confidence limit were plotted.
